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The novel prodrug of butyrlc acid (BA), pivaloyloxymethyl butyrate, has been shown, in vitro. to induce differentiation and inhibit leukemic cell 
proliferation. The prodrug affects the cells in vitro at lower concentration and at least 100 times faster than does (BA). We have compared the 
ability of BA with that of its prodrug AN-9 to modulate the expression of the early regulating genes, c-m~c and c-/q in HL-60 cells. Exposure 
of HL-60 cells to the prodrug resulted in a decrease of C-~ZJY and an increase of c-,lrn expression. The prodrug eliclted this effect at lower 
concentrations and at least 100 times faster than BA. Since changes in the expresslon of c-rwyc and c-jun occur minutes after exposure of the cells 
to the prodrug, these genes are likely to play a major role in the early stages of the differentlatlon pathway. 
c-~ZJY: c-Jun; Butyric acid: Butync acid prodrug: Proliferation; Differentiation 
1. INTRODUCTION 
Leukemias are characterized by a block in the normal 
pattern of differentiation, leading to the accumulation 
of immature cells. Aberrant expression of oncogenes 
may play a causative role in the transformed state of the 
cells [l]. Deregulated c-myc expression plays a pivotal 
role in oncogenesis in a variety of experimental and 
naturally occurring tumors [2]. The promyelocytic HL- 
60 cells have an elevated level Of c-myc expression, at- 
tributed to gene amplification at the DNA level and 
over expression at the RNA level [3,4]. Both c-myc and 
c-&n are early regulatory transcription factors with spe- 
cific DNA binding motifs; c-myc has a helix-loop-helix 
motif and c-&n contains a leucine zipper dimerization 
motif. Homodimers of c-&z or heterodimers of c-junlc- 
fbs form the AP-1 protein that can recognize and bind 
to specific sequences of DNA nucleotides [l]. The ex- 
pression of these genes is linked to proliferation of some 
cells and to the differentiation of others. They are 
among the first genes to be expressed when certain cells 
are stimulated to either proliferate or differentiate [5,6]. 
Butyric acid (BA) was shown to modulate the expres- 
sion of oncogenes and suppresser genes in several cell 
types [7,8]. It is a potent differentiating and anti-prolif- 
erating agent, in a wide spectrum of neoplastic cells in 
vitro [9]; however, in vivo it lacks biological activity, 
due to rapid metabolism [lo]. The novel derivative of 
BA, pivaloyloxymethyl butyrate (AN-9), has been 
shown, in vitro, to induce cytodifferentiation and in- 
hibit leukemic cell proliferation. AN-9 affects the cells 
in vitro at about a lo-fold lower concentration and at 
least 1 OO-fold faster than does BA [ 11,121. While BA has 
no in vivo anti-cancer activity, AN-9 was shown to be 
an effective anti-cancer agent in murine cancer models. 
In this report we have compared the effect of BA and 
its derivative AN-9, on the expression of the early regu- 
latory genes, c-nzvc and c-&n, in HL-60 cells. 
2. MATERIALS AND METHODS 
2 1. Cell culture 
Human promyelocytlc cell line HL-60 was grown as described [l 11. 
Mycoplasma free cells were incubated at 37°C in a humidified CO, 
incubator. Viability was determined by Trypan blue exclusion. 
2.2. Cell prohferatron 
Cell proliferation was measured by mcorporation of [>H]thymidine 
(2 Cl/mmol. Amersham, Little Chalfont, UK) into cells. Cells were 
seeded at a density of 5 x lo4 cells/well in 96-well plates (Cell-Cult). 
During the last 14 h of Incubation. the cells were pulsed with [‘HIthy- 
mldine. 1 @Zl/well. and harvested (MicrotIter Dynatech Cell Har- 
vester) using glass micro fiber filters (Tamar. Israel). 
2.3. Cell dlfferentration 
Cell differentiation was evaluated by Nitroblue tetrazohum (NBT) 
reduction activity [13]. Cell culture containing 0.1% NBT was stimu- 
lated with 400 nM 12-O-tetradecanoyl-phorbol-13-acetate (PMA). 
The cells were incubated for 30 mm at 37°C and examined microscop- 
ically by scoring at least 200 cells. 
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Fig. 1. The effect of BA and AN-9 at low (75 ,uM) and high (500 PM) concentrations on viability, prohferation and differentiation of HL-60 cells. 
The % of viable cells (A). thymidine mcorporation (B) and % of NBT positive cells (C) were determined after exposure of the cells for the indicated 
time intervals. 100% thymldine mcorporatlon (the mcorporation value in untreated cells) was 35.000, 89.000 and 105.000 cpm at 24, 48 and 72 
h. respectively. 
phenol/chloroform extraction. according to Chomczynski and Sacchi 
[14]. RNA 20pg/lane were size fractionated on agarose-formaldehyde 
gel (agarose from BRL, formaldehyde from Sigma) and transferred 
to Nytran filter (Schleicher & Schuell) [15]. The blots were hybridized 
to the following multiprime “P-labeled DNA probes: (1) the I .4-kb 
&I-EcoRI fragment containing the third exon of human c-nzyc 3Rc 
[16]; (2) the l.l-kb &I-EcoRI fragment of human C-/WI [17]. An 
oligonucleotlde probe of human 28s ribosomal RNA (rRNA) labeled 
at the 5’-end (Oncogene Science Cat #ON135) was used throughout 
these studies. to normalize variations m the amount of RNA m indl- 
vidual samples. Appropriate exposures of the autoradiographs were 
scanned using a Zemth Soft Laser scanmng densitometer (model SLR- 
2DIlD). The level of RNA was quantdied by determination of the area 
under each peak with a planimeter. The obtained values were normal- 
ized to the 28s rRNA level and estimated as a percent of the untreated 
cells. This value was termed ‘relative integrated density’ or RID. 
3. RESULTS 
3.1. Effect oJ‘BA and its prodrug AN-9 on HL-60 prolif- 
eration and differentiation - comparative studies 
HL-60 cells were exposed to 75 PM (low) and 500 ,LLM 
(high) concentrations of BA and AN-9, for various time 
intervals. The effect of this treatment on cell viability, 
proliferation and differentiation was determined (Fig. 
1). At 75 PM. AN-9 moderately affected cell viability 
(60~80%), inhibited cell proliferation and induced cell 
differentiation, while BA at the same concentration did 
not exhibit any of the above effects. Cell differentiation 
was determined by the % of NBT positive cells, as de- 
scribed in section 2. The values obtained were: (a) after 
24 h of exposure to the low AN-9 and the high BA 
concentrations the cells exhibited 19% and 13% respec- 
tively; (b) after 36 h the effect of low AN-9 concentra- 
tion was maximal, 39% and the effect of the high BA 
concentration was 32%; (c) only after 48 h the BA effect 
was maximal, 46%, and the AN-9 effect started to de- 
cline slightly to 37% (Fig. IB). The effectiveness of BA 
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at 500 PM and AN-9 at 75 ,uM was similar. whereas 
AN-9 at 500 PM completely inhibited cell proliferation. 
At 500 PM, after prolonged exposure (24 h). AN-9 was 
toxic to the cells (data not shown). However a short 
(30-60 min) exposure of the cells to this concentration, 
resulted in a maximal differentiation induction [I 11. 
Under these treatment conditions the effect of BA and 
AN-9 on the expression of c-myc and c-jun was exam- 
ined. 
3.2. Modulation of c-myc and c-jun expression by BA 
HL-60 cells were exposed to 75 ,uM and 500 ,uM BA 
for various time intervals. The effect of these treatments 
on the expression of c-myc and c-jun mRNA, was fol- 
lowed by Northern analysis (Figs. 2 and 3). At brief cell 
exposure (0.5, 5 and 12 h) to the low concentration of 
BA (75 PM), no effect was seen on the expression of 
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Fig. 2 Modulation of c-WZJY and C-JW expression, in HL-60 cells. by 
BA. Cells were treated with the indicated concentrations of BA for the 
indicated time periods. Total cellular RNA was isolated and analyzed 
for c-nl~~ and c-fun ewpresslon as described m sectlon 2. 
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Fig. 3. Quantitative analysis of c-myc and c-fun expression. Northern blots were probed separately with: c-myc, c-jun and 28s rRNA. RID (relative 
integrated ensity) values were determined as described in section 2. A: 75 ,uM BA; B: 500 ,uM BA. 
these genes (data not shown). A marginal effect (Figs. 
2 and 3) at this low BA concentration was observed only 
after 24 and 48 h. At high BA concentration, the expres- 
sion of c-myc was reduced to 63% of control at 1 h and 
disappeared at 48 h. 
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Fig. 4. Modulation of c-myc and c-fun expression in HL-60 cells by 
AN-g. The cells were treated with AN-9 at the in&cated concentra- 
tions and time intervals. Total cellular RNA was isolated and analyzed 
for c-myc and C-JWI expression. 
The expression of c-&n was enhanced significantly 
only after 48 h of exposure, to low and high BA concen- 
trations. Throughout the duration of the experiment, 
the steady state level of c-vn)?c and c-jun mRNA, in 
untreated cells, did not vary significantly (data not 
shown). 
3.3. ~~du~at~~~ of c-myc and c-&n expression by AN-9 
Exposure of HL-60 cells to the low AN-9 concentra- 
tion resulted in a decrease in c-myc and an enhancement 
in c-&n expression. AN-9 elicited these effects faster and 
at lower concentrations than BA. The following 
changes in the steady state level of the c-myc transcript 
in the cells, were observed: (a) after 15, 30 and 60 min 
exposure to 75 FM AN-9 respective decreases of 23%, 
57% and 72%, followed by complete disappearance at 
5 h, which continued at least up to 24 h; and (b) reap- 
pearance after 48 h (Figs. 4, 5 and 6). At 500 PM after 
5 min a 72% reduction of c-myc transcript occurred and 
at 60 min the gene transcript was undetectable. 
AN-9 at 75 PM enhanced the expression of c-jun 
transcript after 15 min of exposure and a maximum 
expression was achieved at 48 h. The steady-st- level 
of C-~WZ transcript expression which was lop i;~ un- 
treated cells, was somewhat reduced after 15 ant ? min 
following the exposure of the cells to 500 PM A&9. 
4. DISCUSSION 
BA has been shown to be an effective inducer of 
cytodifferentiation in a wide spectrum of neoplastic ells 
in vitro; however, in vivo, it exhibited low potency due 
to rapid metabolism 19,101. Therefore, it is practically 
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Fig. 5 The effect of low concentration of AN-9 on c-WZ_IY and c-jl,n 
expresston in HL-60 cells. Cells were treated with 75 PM AN-9 and 
total cellular RNA was isolated at the mdtcated periods of time and 
analyzed for c-myc and c-jun expresston. 
impossible to achieve an effective BA concentration in 
vivo. Previously we have demonstrated that AN-9 in- 
duces cell differentiation faster and at lower concentra- 
tion than BA and most importantly possesses an in vivo 
anti-cancer activity [11.13]. In this study we have com- 
pared the ability of BA with that of AN-9 to modulate 
; 
i 
bn 2 
the expression of genes which are known to have a 
pivotal role in the differentiation pathway. 
Differentiation of leukemic cell lines was shown to be 
associated with a decrease in c-r)r,t’c expression which is 
necessary and possibly sufficient for induction of cell 
differentiation [ 181. The C-~ZJY and c-ju~l proto-onco- 
gene products, which associate to form heterodimeric 
transcription factors, are among the first genes to be 
expressed when cells are stimulated to proliferate or 
differentiate [ 191. 
AN-9 induces cell differentiation faster than BA (Fig. 
1C). This is in agreement with our previous results 
which have shown that brief cell exposure (less than 1 
h) to AN-9 resulted in cell differentiation [1 I]. while 
only prolonged exposure to BA (48 h). brought about 
a similar effect. 
At optimal concentration, required for the differenti- 
ation induction of HL-60 cells, AN-9 (75 ,uM) and BA 
(500 ,uM) bring about a decrease in c-r~r~c and an in- 
crease in c-jzm steady-state level of expression. After 
exposure of the cells to BA and AN-9. a half-maximal 
change in the level of c-nr~~ expression occurred after 
15 h and 0.5 h respectively. Thus AN-9 at a lower con- 
centration acted 30-fold faster than BA. A half-maximal 
change in the expression of c-&n transcript was 
achieved after 35 h of cell exposure to BA but only 0.5 
h exposure to AN-9. AN-9 enhanced the expression of 
c-j~rz 70-fold faster than BA. These observations suggest 
the involvement of c-~ZJY and c-j~n in the differentiation 
induction mechanism of BA and its prodrug. Further- 
I 
I 
Time 
Ftg. 6. Quantttattve analysts of c-mn.vc and c-fun expresston. Northern blots probed separately with c-DIJC, c-~un and 38s rRNA. Quantttative analysrs 
of c-nr.rc and C-JWI mRNA levels was conducted by densttometric scannmg as described m sectton 2. A, 75 ,DM AN-9; B. 500 PM AN-9. 
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more, AN-9 most likely affects the cells by the same 
mechanism that BA does, but is far more effective. 
Reappearance of c-myc was observed after 48 h. 
Rapid suppression and subsequent re-expression of c- 
IMJ’C was observed previously and was suggested to be 
involved in determining the kinetics of cell commitment 
to terminal differentiation [20,21]. At high concentra- 
tion of AN-9, a dramatic change in the expression of 
C-~ZJYY took place (72% inhibition compared to un- 
treated cells) following a 5 min exposure of the cells to 
the agent and at 1 h c-nz~‘c expression was undetected. 
Unlike the parallel reciprocal changes observed in 
c-nzyc and c-&n expression, at the optimal concentra- 
tion required for differentiation induction, a high con- 
centration of AN-9 does not enhance c-jun expression. 
The initially low expression level of c-jun, at a high 
concentration of AN-9 (500 PM), is further reduced and 
becomes undetectable after 1 h. The differences in the 
pattern of gene expression following treatment with low 
and high AN-9 concentrations, can be explained by the 
differences in the cells’ fate. While the treatment with a 
low concentration of AN-9 leads to cell differentiation, 
with a high concentration of AN-9 it causes cell death. 
The mechanism by which AN-9 (at the high concentra- 
tion) induces cell death, remains to be determined. 
The kinetics of BA and AN-9 induced modulation of 
gene expression, showed that the changes exerted by 
AN-9 are faster than those exerted by BA. This is con- 
sistent with AN-~‘S rapid mode of action and further 
supports the notion that it acts as a true BA prodrug. 
The superior pharmacokinetics of AN-9 may stem from 
either a faster rate of intracellular penetration by the 
lipophilic AN-9 and/or a slower rate of metabolic degra- 
dation. The in vivo anti-cancer activity of AN-9 might 
be attributable to its pharmacokinetic properties. 
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